Halozyme Appoints Darren Snellgrove as Chief Financial Officer

Halozyme Therapeutics Inc. has appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026.

Snellgrove will be responsible for leading Halozyme’s financial operations and strategy, including capital allocation, corporate development and investor relations. He will report to Helen Torley, President and Chief Executive Officer.

“I am delighted to have a financial leader of Darren’s experience and caliber join Halozyme at this exciting time. He is a highly respected finance leader with deep experience and an expansive skillset, demonstrated by successful leadership across major portfolio investments and a strong, well-established record of investor engagement,” said Torley. “I look forward to having Darren join our leadership team and contribute to the acceleration of value creation for our shareholders.”

Experience

Snellgrove brings more than 30 years of financial leadership, strategic insight, and operational excellence across the biopharmaceutical and medtech sectors. Most recently, he led investor relations at Johnson & Johnson where he reshaped corporate messaging and investor engagement strategies, strengthened analyst and shareholder relationships, and supported strong market performance.

Previously, Snellgrove served as Chief Financial Officer of Johnson & Johnson’s Pharmaceuticals sector, where he provided global financial leadership for a business generating more than $50 billion in annual revenue. During his tenure, he lead large global teams across commercial operations, R&D, supply chain, and business development, and played a central role in major portfolio investments, restructuring initiatives, and business development transactions.

Earlier in his career, Snellgrove held CFO and senior finance leadership roles across pharmaceutical R&D, innovation, and M&A at Johnson & Johnson, as well as progressive finance roles at Centocor prior to its acquisition.

Snellgrove holds an MBA from Villanova University and a BA Honors degree from the University of Southampton in England.

“I am thrilled to join Halozyme at such an important time in the Company’s evolution,” said Snellgrove. “Halozyme’s technology has dramatically improved the delivery of biologics for patients, and the company has built a broad technology portfolio with strong partners, durable royalty streams, and significant long‑term opportunity. I look forward to working with Helen and the entire team to drive sustainable growth and value creation for shareholders.”